PREX2 and melanoma: Our hypothesis was that if the enhanced response to MAPK observed following genetic targeting of PREX2 or pharmacologic targeting of p110β/δ acted via the same mechanism, no additional benefit for should be elicited by targeting melanomas lacking functional PREX2 with AZD8186.